NCIC CLINICAL TRIALS GROUP

INVESTIGATIONAL NEW DRUG COMMITTEE

DISEASE SITE COMMITTEE MEETING

OPEN AGENDA

Friday, April 28, 2006 ~ 13.30 – 16.30
Room: Mont Royal/Hampstead

Chair: Gerald Batist

1:30 p.m. Welcome

TRIAL REPORTS

IND.152 Phase II PS-341 Waldenstrom’s E. Eisenhauer
IND.160 Phase II CCI-779 Endometrium A Oza
IND.167 Phase II Bay 43-9006 Prostate K Chi
IND.171 Phase I (NSCLC portion): AZD2171 + carboplatin/paclitaxel S Laurie

2:00 p.m. EDUCATIONAL SESSIONS (15' COFFEE BREAK MID AFTERNOON)

(15') Report from Health Canada Dr. C. Nestruck Health Canada
(20') Oncolytic Viruses as Cancer Therapeutics J. Bell Ottawa Hospital Research Institute
(20') Early Development of Targeted Anti-cancer Agents: Endpoints and Designs J Dancey Cancer Therapy Evaluation Program, NCI Bethesda
(20') The use of pharmacogenomics to improve cancer therapeutics C. Guillemette, Canada Research Chair in Pharmacogenomics, Laval University
(20') NCIC CTG: Drug Development Fellowship Report I Gauthier, Ottawa Hospital Research Institute

4:00 p.m. New / Planned Studies, Report from Closed IND meeting, & IND executive EE/LS/GB

4:25 p.m. Thank-you to Gerry Batist!

4:30 p.m. Adjourn